anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition comprises treated immunized camelid milk in an acceptable vehicle for the treatment or prevention of skin or mucous membrane diseases. Preferably the camelid is from the genus camelus, llama or vicuna and is preferably camelus dromedarius (dromedary or Arabian camel or Indian camel). The camelid is preferably immunized with a gastrointestinal pathogen selected from Propionibacterium acne, Staphylococcus aureus, Streptococcus mutans, Pseudomonas aeruginosa, Haemophilus influenza, Neisseriae spp. Candida spp. or Chlamydia trachomatus. A process for preparing the composition is outlined comprising: immunizing a female camelid with a vaccine of Propionibacterium acne, Staphylococcus aureus, Streptococcus mutans, Pseudomonas aeruginosa, Haemophilus influenza, Neisseriae spp. Candida spp. or Chlamydia trachomatus; obtaining milk from the camelid; treating the milk at a temperature of 0oC for 1-2 hours and centrifuging at 15000rpm to remove lipids; treating the milk with rennin or acetic acid to reduce protein content; pasteurising the milk at a temperature ranging from 65oC to 72oC for 15 minutes; and preparing the milk in an acceptable carrier to be used for skin or mucous membrane infections.
Increased glycolysis and reduced oxidative phosphorylation is a characteristic property of many tumors. A change of nutrition by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and therefore inhibit tumor growth. Standard treatment for glioblastoma includes resection, irradiation and temozolomide chemotherapy. If there is tumor recurrence, no standard therapy is established. Therapeutic options in this situation include resection, irradiation or another chemotherapy. However, some patients cannot be treated in this situation, because none of the available treatment options seems reasonable or applicable, for example if no additional chemotherapy can be started at the time of recurrence due to myelosuppression. The pilot study examines whether in this situation a ketogenic diet can be applied to the patients and may inhibit tumor growth and influence the quality of life of the patients.
BACKGROUND: Cancer is associated with an increased risk of atrial fibrillation. Whether cancer is also associated with atrial cardiopathy, another atrial pathology associated with heightened ischemic stroke risk, is uncertain.
METHODS: We conducted a retrospective cross-sectional study among consecutive patients hospitalized with acute ischemic stroke at a quaternary care center in New York, United States from 2011 through 2016. The study exposure was active cancer. The study outcome was atrial cardiopathy, defined as a left atrial volume index ≥35 mL/m2 on echocardiography. We used multivariable logistic regression, adjusting for baseline characteristics, to evaluate the relationship between cancer (active or historical) and atrial cardiopathy. We performed a subgroup analysis among patients with embolic stroke of undetermined source (ESUS).
RESULTS: The final cohort included 1104 patients with acute ischemic stroke, of whom 10 % had active cancer and 47 % had atrial cardiopathy. Patients with atrial cardiopathy, compared to those without, were older (median age, 77 versus 68 years), and more frequently had hypertension, coronary disease, and atrial fibrillation. Active cancer was present in 9.6 % of patients with atrial cardiopathy (n = 50/520) and 10.4 % of patients without (n = 61/584). There was no association between active cancer and atrial cardiopathy among the overall ischemic stroke cohort (adjusted odds ratio [OR], 0.91; 95 % confidence interval [CI], 0.60-1.37) nor in patients with ESUS (aOR, 0.64; 95 % CI, 0.30-1.36). When the cancer exposure was broadened to include any history of cancer (n = 236, 21.4 %), there still was no significant association with atrial cardiopathy (aOR, 0.93; 95 % CI, 0.68-1.25).
CONCLUSIONS: When defining atrial cardiopathy by left atrial volume, we did not find an association between cancer and atrial cardiopathy in patients with ischemic stroke, including among those with ESUS. Future studies, evaluating other atrial cardiopathy biomarkers and settings, are needed to further investigate any potential link between cancer and atrial cardiopathy.
272,567. MacEwen, S. R. Dec. 17, 1925. Hypodermic injections.-Solutions of arsenical drugs which are derivatives of dioxydiaminoarsenobenzene are prepared by dissolving the drug in water together with a sugar and a soluble salt of a phospho-acid, such as an acid phosphate, phosphite or hypophosphite. Solutions ready for injection are prepared and put up in sealed ampoules, and are stated to keep for long periods without developing toxicity. Arsenical drugs specified are arsphenamine, neoarsphenamine and sulpharsphenamine, whilst dextrose is mentioned as a suitable sugar. A little alkali may be added to the solutions to inhibit any gel formation. Tables are furnished showing the preservative action of dextrose alone, of sodium acid phosphate alone, and of the two substances together on solutions of neoarsphenamine. Specifications 112,984 and 221,565 are referred to.
Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Relapsed or progressive solid tumors and leukemias have a very poor prognosis in children despite intense multimodal treatment protocols involving polychemotherapy, surgery, and radiation. Therefore, innovative treatment strategies targeting specific molecular mechanisms are urgently required. A novel class of compounds with promising anti-tumoral activities is histone deacetylase (HDAC)-inhibitors. HDACs are key enzymes involved in regulation of chromatin-structure and function of several proteins, and aberrant activities of HDACs are found in many cancer cells. Pharmacological inhibition of HDACs causes cell cycle arrest, apoptosis, differentiation, inhibition of clonogenic growth, and anti-angiogenic effects in numerous cancer cells. In addition, promising anti-tumoral activity has been shown in several pre-clinical pediatric tumor models such as neuroblastoma, medulloblastoma, glioblastoma, retinoblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, ATRT, and acute lymphoblastic leukemia. Several HDAC inhibitors are now in Phase I-III clinical trials in adult patients demonstrating a good safety profile and promising anti-neoplastic activity. The first of these compounds, suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), was recently approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma. Vorinostat showed linear pharmacokinetics, good oral bioavailability and a broad range of anti-tumor activity in a Phase I clinical trial including 73 adult relapsed tumor patients. The determined peak plasma levels were in the range of 658±439 ng/ml (corresponding to 2.5±1.7 µM). At these concentrations, anti-tumoral effects on pediatric cancer cells and leukemias have been documented in vitro. Furthermore, vorinostat passes the blood brain barrier in mice, thus making it a suitable compound for the treatment of brain tumors.

The aim of this study is to define a dose recommendation of vorinostat in pediatric oncology, to determine pharmacokinetics of vorinostat in children, determine response rates, safety and feasibility. The design is an open, multicenter Phase I/II trial. Children and adolescents (3-18 years) with relapsed or therapy-refractory solid tumor, lymphoma or leukemia following standard treatment protocols in pediatric oncology will be included. 50 patients will be recruited over 2 years. Vorinostat will be taken orally once per day on an outpatient basis and the dose will be escalated until the individual maximum tolerated dose is established. This dose will then be applied for 3 months, when tumor response will be evaluated. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months. After end of treatment (EOT) follow-up evaluations will be performed for 3 months. Pharmacokinetic studies will be performed in plasma, and in optional cerebrospinal fluid samples. Biomarkers (BMP4, IL-6, IL10 induction following Vorinostat treatment, basal histone acetylation, HDACs and H23B in archived tumor samples) will be determined and correlated with treatment response.
Healthy Choices is a randomized clinical trial examining the efficacy of motivational enhancement in reducing risk and promoting healthy behaviors. This study will use a sample of 225 youth (180 after attrition), ages 16-24, of whom 90 will receive the intervention, referral, and standard care, and 90 will receive referral plus standard care. The sample will be drawn from five study sites. Using parallel screening, recruitment will target 100 youth with an adherence problem, 100 youth with a substance use problem, and 25 youth with a sexual risk problem. A repeated measures design will be used for the proposed study. Primary outcome measures are drug and alcohol use, condom use, and HIV medication adherence. Youth will complete an initial data collection session (baseline) during which questionnaire and interview measures will be administered. Blood specimens for viral load and CD4+ count will also be obtained.

Randomization procedures will take place after completion of the baseline assessment. Participants who are randomized to the intervention group will participate in four sessions for approximately 3 months and will also receive standard care plus individualized referrals. The control group will receive standard care and individualized referrals. All five sites offer comprehensive, multidisciplinary care including social work and case management services and access to mental health services. Participants will receive a three-month post-test designed to coincide with ME completion. Subsequent post-tests will occur at 6, 9, 12, and 15 months after baseline data collection (3, 6, 9, and 12 months after ME completion).
TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
When a naïve observer meets with a familiar conspecific in pain, mice may have a myriad of social (sniffing, allolicking, allogrooming, huddling) and non-social (self-grooming) behaviors under dyadic social interaction (DSI) paradigm. Unlike male, female observers express more allolicking behavior toward injury site of a familiar female in pain, but with less body allogrooming. In current study, we investigated roles of natural estrus cycle phases and ovarian estrogen in these behaviors and results showed that: (1) there was no changes in above behaviors in terms of latency, time and bouts across different natural estrus cycle phases in intact female. (2) however, ovariectomy (OVX) changed estrus cycle phases, lowered circulating level of ovarian estrogen, reduced time and bouts of allolicking behavior and increased time of self-grooming without affecting other behaviors. Moreover, OVX in observers decreased social buffering effect of DSI on spontaneous pain-related behavior in demonstrator relative to naïve and sham controls. (3) treatment of OVX-female with β-estradiol (E2) or progesterone (PROG) as replacement therapies, only E2 reversed impairment of allolicking behavior. (4) Additionally, socially transferred pain could be identified in intact female across all estrus cycle phases post-DSI, but disappeared in OVX-female, which could be reversed completely by E2 but not by PROG. (5) Finally, serum levels of estrogen, PROG, oxytocin, arginine vasopressin (AVP), prolactin, norepinephrine and 5-HT were examined by ELISA after E2, results showed only AVP level was significantly increased. These results suggest both injury site-targeted caring behavior and socially transferred pain are selectively dependent on ovarian estrogen. This article is part of the Special Issue on "Empathic Pain".
Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
UNLABELLED: The needs of well siblings of children with chronic pediatric conditions (CPCs) are often overlooked as parents tend to direct their attention toward the child with CPC. This highlights the need to explore the experiences of these siblings to better inform the implementation of healthcare services. To consolidate the most up-to-date qualitative evidence regarding well siblings' perceptions and experiences of living with children with CPC. This qualitative systematic review was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The search was conducted on eight electronic databases from their respective dates of inception to March 2024. Sandelowski and Barroso's (2007) two-step approach was used to synthesize findings. Review findings were assessed using the Grading of Recommendations Assessment, Development, and Evaluation-Confidence in the Evidence from Reviews of Qualitative research approach. In total, 23 studies (published between 2014 and 2023) were included. This review included 269 well siblings (aged between 7 and 23 years old) and 74 parents (mostly mothers). Four highly connected themes were identified: (1) A whirlpool of emotions, (2) Coping behaviors, (3) Growing up way too early, and (4) Doing and hoping for the best.
CONCLUSION: This review emphasizes the necessity for healthcare professionals to attend to the emotional and psychosocial needs of well siblings, and educate parents on how to better address well siblings' needs. Future research could look into the experiences of siblings of children with less common CPCs.
WHAT IS KNOWN: • The specific needs of well siblings of children with chronic pediatric conditions are unexplored. • Well siblings have difficulty comprehending and adapting to their sibling's chronic condition upon diagnosis.
WHAT IS NEW: • Interactions between family members and healthcare professionals play a crucial role in shaping how well siblings understand their siblings' chronic conditions. • Well siblings adopt various ways to help them cope with these challenging circumstances. • Well siblings are at risk for psychological distress upon learning about their sibling's chronic conditions.
Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
Participants assigned to standard care will follow-up with a stroke provider within 2 weeks of discharge and primary care as per usual recommendations. Participants will monitor their blood pressure on their own and pharmacists will contact participants monthly to review blood pressure. Pharmacists will make recommendations for blood pressure medication adjustment to participant primary care provider.
A container assembly configured to maintain a predetermined humidity for storing a product therein. The container assembly includes a container having a body with a body wall and a mouth opening into a storage cavity and a cap having a top wall. The cap is selectively mountable over the mouth of the container to substantially enclose the storage cavity in a mounted configuration. A sidewall extends substantially perpendicularly from one of the body wall and the top wall. The sidewall defines an opening and a compartment and has an opening edge adjacent the opening. A moisture control material is positioned within the compartment. A sealing membrane has a peripheral portion. The peripheral portion is secured to the sidewall proximate the opening edge. The sealing membrane is configured to allow moisture flow therethrough to maintain the predetermined humidity in the storage cavity.
Disclosed is a method of preparing finely divided cartilage powder from raw cartilage including the steps of mechanically trimming raw cartilage from an animal body, and granulating the raw cartilage into granules having an average size of from about 4 mm to 8 mm diameter. The granules are then subjected to azeotropic extraction, the extraction conducted with an extracting agent which both forms an azeotrope with water and solubilizes fat. The granules are then separated from the extracting agent, and milled to an average size of from about 40 to 70 mu  diameter. Also disclosed is a method of separating calcium compounds from cartilage including the steps of mechanically trimming raw cartilage from an animal body, granulating the raw cartilage into granules having an average size of from about 4 to 8 mm diameter, and partially drying the granules to produce a friable calcified outer layer on each granule. The granules are then subjected to mechanical agitation to pulverize the friable calcified outer layer and separated from the pulverized calcified outer layer. Also disclosed is a method of preparing finely divided cartilage powder involving a freeze-drying step.
This is a minimal-risk, behavioral clinical trial for adult parents and their children (2;6-4;0). The purpose of this study is to determine if and how parent language skills and behavioral awareness influence early language interactions and parent training. Participants will include parent-child dyads in three groups: 1) children who are typically developing (TD; Study 1 and 2), 2) children at risk for persistent developmental language disorder (DLD; Study 1 and 2), and 3) children with autism spectrum disorder and at risk for persistent DLD (ASD+DLD; Study 2). The investigators will examine whether parental language skills predict early language interaction quality (Aim 1; Study 1), whether parental behavioral awareness predicts modifiability during training (Aim 2; Study 2), and whether these predictors vary across children-specifically TD children, children with DLD, or with ASD+DLD (Aim 3; Study 2). The primary outcome measure will be parents' use of language stimulation strategies. The secondary outcome measure will be the number of adult-child conversational turns. The investigators hypothesize that parent language skills (Study 1) and behavioral awareness (Study 2) will be positively associated with the outcomes. However, the strength of the association may vary across the groups. The Study 1 protocol will involve a screening session and observational data collection sessions (TD and DLD groups). Study 1 will be a fully remote model of data collection. The Study 2 protocol will involve five sessions-baseline data collection (all groups), three parent training sessions (DLD and ASD+DLD), and follow-up data collection (all groups) across approximately five weeks. Study 2 will be fully remote. The investigators will collect data from demographic questionnaires, language and learning assessments, measures of parental behavioral awareness, and measures of parent-child language interaction quality (Study 1 and 2). These measures will be administered before and after three parent training sessions (Study 2). These sessions will follow the Teach-Model-Coach-Review framework (TMCR; 1) to train the Enhanced Milieu Teaching (EMT) strategies of responsive interaction, matched turns, language modeling, and expansions. After the training, parent-child dyads will complete the structured interaction and behavioral awareness tasks again (Study 2). The investigators will conduct inter- and intra-group analyses to explore the relationships between the independent (i.e., parent language abilities and behavioral awareness) and dependent (i.e., parent-child language interaction quality and parent modifiability during training) variables.
The invention discloses snake oil burn oil solution for external use. The snake oil burn cream is a Chinese medicament oiling agent for external use which is used for treating the symptoms of burned and scalded injury, frozen wound, diabetic foot, corneal burns, inhalation lung injury, bedsore and the like. The snake oil burn cream is developed and prepared by years and is selected and used after clinical practice verification. The snake oil burn cream consists of snake oil, polygonum cuspidatum, borneol, garden burnet,scutellaria baicalensis and musk. The traditional Chinese medicaments, such as polygonum cuspidatum, the garden burnet and the scutellaria baicalensis, are dried, smashed and decocted; the mixture is purified by adopting a distillation technology; and the snake oil, the borneol, the musk are added into the purified mixture and are decocted to obtain the oiling agent. The snake oil burn cream is reasonable in formulation, has clear rules of treatment in all parties, and the effects of moisturizing skin, promoting granulation, diminishing inflammation, relieving pain, eliminating swelling and the like, and can treat the symptoms of burned and scalded injury, frozen wound, diabetic foot, corneal burns, inhalation lung injury, bedsore and the like. The snake oil burn cream has a good treatment effect, quick effect, convenience in use, safety and reliability, the efficiency reaching 100 percent, the effects of treating both principal and secondary aspects of disease, and can fulfill the aim that the symptoms are not easy to recur after curing. The snake oil burn cream has good effects on ligament burn repair and other persistent open skin damages.
The disposable stimulus/recording electrode array for the TwitchView will be placed on one of the patient's wrist/hand and connected to the device. Next, the stimulating electrodes and vibration sensor of the QTOF device will be placed over the contralateral ulnar nerve and thenar eminence. The devices will be placed prior to the induction of anesthesia - but no electrical stimuli will be delivered until AFTER the patient is asleep (as per routine). After induction, both devices will be started. The TwitchView automatically selects the appropriate stimulus current (takes about 10 seconds) - and when that is complete, the QTOF stimulus current will be set to the same value. The stimulus interval for both devices will be 20 seconds. Paired measurements of twitch count and TOF ratios will be gathered for the entirety of the surgical procedure, and cross checked with Epic regarding the administration of neuromuscular blocking drugs (time, dose) and reversal agents (time, dose). RAs will be present to verify the correct function of both devices. Note that information from the TwitchView monitor will be continuous available to the providers (it is a standard device available for use in our ORs). Information from the QTOF will NOT be made available to providers.